New Research shows Anti-Aging Effects of two Molecules!

Summary

• Senescent cells and aging: Senescent cells have stopped dividing, a state that can help prevent cancer. They can nevertheless remain active by releasing inflammatory and tissue-altering molecules, collectively known as the senescence-associated secretory phenotype (SASP). These cells tend to accumulate with age.
• Senolytics: Senolytics are compounds intended to remove senescent cells. The video discusses dasatinib and quercetin, often studied together, as well as fisetin. Human studies suggest senolytic treatment can reduce senescence-associated markers such as p16, p21, and beta-galactosidase in fat tissue. In one study described, reductions were still seen nearly two weeks after a three-day treatment.
• Reported clinical outcomes: The video describes a small Phase II trial in which a pulsed, three-week senolytic regimen was associated with improvement or regression of metabolic-associated steatohepatitis (MASH) in over half of participants. The presenter stresses that this did not mean participants were cured.
• Other areas under study: Human research has also examined senolytics in conditions such as pulmonary fibrosis, skin changes, osteoarthritis, and bone health. Results are not uniformly positive.
• Limitations and cautions: The human evidence is still limited: studies are small, some are unblinded, and differences in dose, protocol, or outcomes may help explain mixed findings. Reported side effects include headaches and gastrointestinal problems, though safety data are also limited. The video concludes that senolytics are promising but not sufficiently tested to recommend broadly, particularly for younger adults.

Researchers and sources featured

The video subtitles do not name researchers directly. The accompanying metadata lists these study references:

• Hickson LJ, Langhi Prata LGP, Bobart SA, et al. “Senolytics decrease senescent cells in humans: preliminary report from a clinical trial of dasatinib plus quercetin in individuals with diabetic kidney disease.” EBioMedicine, 2019.
• Farr JN, Atkinson EJ, Achenbach SJ, et al. “Effects of intermittent senolytic therapy on bone metabolism in postmenopausal women: a phase 2 randomized controlled trial.” Nature Medicine, 2024.
• Justice JN, Nambiar AM, Tchkonia T, et al. “Senolytics in idiopathic pulmonary fibrosis: results from a first-in-human, open-label, pilot study.” EBioMedicine, 2019.
• Martyanov V, Whitfield ML, … A further reference appears in the metadata, but its citation is cut off.